Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline BioSpaceDenali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year.NeuroscienceRead full story pharminent June 19, 2026 (Last updated: June 22, 2026) BioSpace Denali Therapeutics is the latest company to sell a priority review fast pass for an elevated price after the program was renewed earlier this year. Neuroscience Read full story Post navigation Previous: US launches probe of German ‘underpayment’ for medicinesNext: Japan approves Sanofi’s Sarclisa combo for MM treatment Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026